AllSci News
Dyne secures USD 400m debt facility to fund dual neuromuscular launches without dilution
Waltham, Massachusetts-based Dyne Therapeutics, Inc. (Nasdaq: DYN) announced an amendment to its existing non-dilutive senior secured term loan facility...
Michael J. Fox Foundation backs Neuron23's LRRK2 trial expansion into Israel
South San Francisco-based Neuron23 has received a USD 2.5 million grant from The Michael J. Fox Foundation for Parkinson's Research to expand its NEULARK...
Vedana launches with USD 46 million to challenge CGRP monopoly in migraine prevention
Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based...
Rigel acquires first-ever PROTAC approval with USD 70 million Veppanu deal from Arvinas and Pfizer
Rigel Pharmaceuticals (Nasdaq: RIGL) has closed its exclusive global license for VEPPANU (vepdegestrant), paying USD 70 million upfront to Arvinas (Nasdaq:...
Triveni Bio secures USD 65 million to expand first-in-class bispecific antibody into atopic dermatitis
Watertown, Massachusetts-based Triveni Bio Inc., a clinical-stage biotechnology company developing antibody therapies for immunological and inflammatory...
Verastem's RAF/MEK-FAK strategy shows encouraging survival signal in pancreatic cancer
Updated data from the RAMP 205 trial show that avutometinib plus defactinib, layered on top of gemcitabine and nab-paclitaxel, produced a 52% confirmed...
NIDA renews support for Northeastern cannabinoid drug discovery program
Northeastern University has received a USD 1.43 million NIDA P01 program project renewal to advance structure-guided drug discovery targeting CB1 and CB2...
Rutgers researchers explore PARP1 inhibition as strategy against chemotherapy-related cognitive impairment
Rutgers Biomedical and Health Sciences has received a USD 1.78 million National Cancer Institute R01 award to identify biomarkers and evaluate therapeutic...
ScinnoHub launches Phase I study of RET inhibitor aimed at post-Retevmo/Gavreto resistance
China-based ScinnoHub Pharmaceutical Co., Ltd. has initiated a first-in-human Phase I trial of SNH-118110, an oral small-molecule RET inhibitor, in patients...
NMD Pharma reports functional gains for CIC-1 inhibitor in CMT despite Phase IIa endpoint miss
Functional improvements in hand grip strength and composite motor measures in Charcot-Marie-Tooth disease patients — sustained a week after treatment...
Akeso revives CD47 strategy in AML after strong Phase II showing for ligufalimab
A randomized, placebo-controlled Phase II trial of ligufalimab, a CD47-targeting antibody, has reported survival data in treatment-naïve AML that positions...
Bayer completes USD 2.45b purchase of Perfuse for first-in-class endothelin antagonist
Bayer has completed its acquisition of Perfuse Therapeutics, gaining full global rights to PER-001, a first-in-class sustained-release endothelin receptor...
Zydus expands US oncology footprint with USD 166 million Assertio acquisition
India-based Zydus Lifesciences (NSE: ZYDUSLIFE) completed its acquisition of Lake Forest, Illinois-based Assertio Holdings, Inc. (Nasdaq: ASRT) on June 16,...
Edgewise's EDG-7500 opens potential path in nonobstructive HCM beyond myosin inhibitors
EDG-7500 hypertrophic cardiomyopathy data from Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) are pointing toward a mechanistically distinct...
Trellis opens inhaled antibody route to tackle lung infections resistant to systemic therapy
Redwood City, California-based Trellis Bioscience LLC is advancing a first-in-human trial of inhaled TRL1068, a human monoclonal antibody designed to...
The AllSci Brief
Free, systematic R&D and deal news. Daily.